A coalition of 43 state attorneys general has filed a sweeping lawsuit accusing pharmaceutical giant Novartis and its former subsidiary Sandoz of orchestrating a massive bid-rigging scheme for 31 generic drugs, calling it one of the most brazen conspiracies ever uncovered in the industry.
Swiss pharmaceutical giant Novartis forecasts a low single-digit percentage decline in its 2026 operating profit, citing intensifying pressure from generic rivals to key drugs like Entresto.
The Swiss pharma giant reported robust 2025 results, hitting a key profitability goal early. While facing near-term pressure from U.S. generic competition, CEO Vas Narasimhan outlined a strategy anchored by a portfolio of growth brands and a promising late-stage pipeline.
As Teva Pharmaceutical shifts focus from its legacy generics business to a promising innovative pipeline, its experimental drug Duvakitug emerges as a potential valuation catalyst. We examine the bull case, the competitive landscape, and what it means for investors.
The Danish pharmaceutical giant forecasts a significant drop in revenue for the year, citing fierce competition for its weight-loss drugs and U.S. government pricing initiatives. The projected decline steeper than analyst expectations triggered a sharp sell-off in its U.S.-listed shares.
Pharmaceutical giant Eli Lilly announces a major investment in a new Lehigh Valley manufacturing site, set to create hundreds of jobs and bolster U.S. production capacity for its in-demand injectable therapies, including weight-loss drugs.
A provocative analysis suggests the widespread adoption of GLP-1 drugs like Ozempic and Wegovy could trim airline fuel bills by reducing passenger weight, potentially passing savings to travelers. But industry experts debate whether the math adds up.
A new Fox News survey reveals Democrats leading Republicans 52% to 46% in a generic congressional ballot for the 2026 midterms, the highest level of support recorded for either party in this poll series. Voter priorities and sharp partisan divides on key issues shape the early political landscape.
Eli Lilly's surging sales of its GLP-1 drugs contrast with Novo Nordisk's profit warning, signaling a potential shift in the competitive landscape for obesity treatments, while increased competition and generic drugs begin to pressure prices.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
A new wave of advanced GLP-1 therapies from Eli Lilly, Novo Nordisk, and Amgen, valued at a combined $68 billion, promises to reshape the obesity treatment landscape with improved efficacy and convenience.
Eli Lilly's fourth-quarter revenue surged 42.6%, fueled by overwhelming demand for its weight-loss and diabetes treatments. The pharmaceutical giant's robust performance and bullish outlook underscore its dominant position in the fast-growing GLP-1 market.
Driven by blockbuster sales of its weight-loss and diabetes treatments, Eli Lilly's 2025 revenue surged 45%, with the company forecasting even stronger growth for 2026 as it prepares to launch a pivotal oral therapy.
Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, saw its market value plummet by billions after forecasting a significant sales decline for the year, driven by falling drug prices in its crucial U.S. market.
Biopharmaceutical firm Ardelyx has been granted a crucial U.S. patent covering the oral formulation of its drug tenapanor, solidifying protection for its commercial products Ibsrela and Xphozah until late 2042 and bolstering its competitive position in the chronic kidney disease treatment landscape.
GSK's annual net profit more than doubled in 2025, fueled by robust sales of HIV, respiratory, and oncology medicines. The results signal a strong recovery for the pharma giant after settling costly U.S. lawsuits related to its discontinued heartburn drug Zantac.
This year's Super Bowl advertising lineup is dominated by wellness themes, but the most consequential push comes from telehealth companies and pharma giants seeking to reshape the narrative around blockbuster GLP-1 medications, moving beyond weight loss to broader health benefits.
As millions tune in for the big game, advertisers are betting millions more on a mix of cutting-edge tech, health trends, and celebrity power to capture viewer attention, making this year's commercial lineup a cultural barometer of its own.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
